Inhibiting IP6K1 confers atheroprotection by elevating circulating apolipoprotein A-I.
Liu X, Zhang Z, Aguirre T, Shipton ML, Fu L, Du J, Furkert D, Qi J, Chin AC, Riley AM, Liu T, Zhang X, Potter BVL, Fiedler D, Zhu Y, Fu C.
Liu X, et al. Among authors: zhu y.
Metabolism. 2024 Dec 4:156098. doi: 10.1016/j.metabol.2024.156098. Online ahead of print.
Metabolism. 2024.
PMID: 39643078